Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Cipla Limited
EIR
•Cipla Limited•January 28, 2019

Cipla Limited – FDA EIR, Jan 28, 2019

Record Details

Cipla Limited, located in Vasco Da Gama, Goa, India, underwent a comprehensive surveillance inspection by the U.S. Food and Drug Administration (FDA) from January 21 to January 28, 2019. The inspection was conducted under various compliance programs, including those for pre-approval inspections, animal drug manufacturing, and foreign drug inspections, to assess the facility's adherence to regulatory standards for drug product manufacturing. A prior inspection in September 2018 also resulted in observations, which the firm subsequently addressed, leading to a Voluntary Action Indicated (VAI) classification. During the recent inspection, the FDA issued a Form FDA 483 with six significant observations. These included deficiencies where the quality unit failed to ensure all errors were fully investigated and good aseptic behaviors were not consistently practiced. Furthermore, master production and control records were found to be insufficient, and equipment was not always appropriate for its intended use. Issues also concerned drug product release testing, which was not consistently adequate, and stability study samples not being stored under worst-case conditions. In response, Cipla Limited's management acknowledged the observations, committed to implementing necessary corrections, and agreed to provide a written response to the FDA within 15 business days. The FDA cautioned that failure to make timely corrections could result in further regulatory actions, including a warning letter or import detention. The inspection concluded with a classification of Voluntary Action Indicated (VAI), signifying that while not critical, the identified deficiencies require formal corrective actions.

Company
Cipla Limited
Inspection date
January 28, 2019
Product type
drugs
Office
Office of Regulatory Affairs
People
  • Cheryl A. Clausen
  • Kevin A. Gonzalez (Branch Chief, Foreign Pharmaceutical Quality Inspection at FDA)
View Company Profile

ID · a706c6c3-0594-4c74-9fdc-cad98c532f4e

Other documents for Cipla Limited
  • 483 - 2026-04-17April 17, 2026
  • 483 - 2024-06-21June 21, 2024
  • 483 - 2022-08-26August 26, 2022
  • 483 - 2019-09-27September 27, 2019
  • 483 - 2019-01-28January 28, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Cipla Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.